Abstract:Purpose: CD19 is a cell surface protein that is found on both healthy and malignant B cells. Accordingly, it has become an important target for novel treatments for non-Hodgkin lymphomas and B-cell leukaemia. Three anti-CD19 monoclonal antibodies with distinct mechanisms of action have been developed for the treatment of B-cell malignancies. Methods: We reviewed the preclinical and clinical data on the development of the newly approved anti-CD19 monoclonal antibodies blinatumomab, tafasitamab and loncastuximab tesirine, and consider their place in the treatment of relapsed or refractory B-cell malignancies. Results: Blinatumomab is a bispecific T-cell engager that binds to both CD19 on B cells and CD3 on T cells, facilitating antibody-dependent cytotoxicity. Blinatumomab significantly prolongs overall survival in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, although cytokine release syndrome and severe neurotoxicity may necessitate discontinuation. Tafasitamab, which has modified anti-CD19 Fab and Fc regions, has significantly enhanced affinity for both CD19 and effector cell receptors compared with unmodified anti-CD19. In L-MIND, tafasitamab plus lenalidomide provided an overall response rate (ORR) of 57.5% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients non-transplant eligible. Loncastuximab tesirine is an antibody-drug conjugate that has been studied as monotherapy and in combination with ibrutinib in 3L + relapsed or refractory DLBCL. The ORR was 48.3% in a phase II trial of loncastuximab tesirine. The optimal place of anti-CD19 monoclonal antibodies in therapy has yet to be determined, but the prospect of improved outcomes for at least some patients with treatment-resistant B-cell malignancies appears likely, particularly in those with limited therapeutic options and poor prognosis.

[Monoclonal antibody therapy for malignant lymphoma]

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia

Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

Novel Anti-Cd20 Antibody Tgla with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Mediates Potent Anti-Lymphoma Activity

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Monoclonal Antibodies in the Treatment of Multiple Myeloma

Advances of Rituximab in the Treatment of Malignant Lymphoma

[Advancement of Biotherapy for Malignant Lymphoma].

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma

T Cell-Based Targeted Immunotherapies For Patients With Multiple Myeloma

Novel Immunotherapies for Adult Patients with B-lineage Acute Lymphoblastic Leukemia

Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia

[Lymphomas: A therapeutic update]

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.

Advances in Lymphoma Maintenance Therapy with Rituximab